Skip to main
XOMA

XOMA (XOMA) Stock Forecast & Price Target

XOMA (XOMA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

XOMA Royalty Corp is projected to experience robust revenue growth, with a forecasted increase of over 20% annually through 2026, driven by the commercial success of products including Vabysmo, Ojemda, and Miplyffa. The company reported a significant rise in total income from royalty agreements, reaching $28.5 million in 2024, up sharply from $4.8 million in the previous year, suggesting effective management of purchased receivables and customer contracts. Looking forward, XOMA anticipates generating revenues of $49.0 million by 2026, alongside potential contributions from earlier-stage assets and milestone payments, bolstering the company's financial outlook.

Bears say

XOMA Royalty Corp's revenues and net earnings have historically exhibited significant variability, largely attributable to the international market dynamics affecting its operations and services provided to pharmaceutical and biotechnology firms. The company is exposed to potential economic downturns, changes in governmental reimbursement policies, and tariffs, all of which could adversely impact its operational capabilities and market performance. Additionally, factors such as failed clinical trials, the departure of key executives, and the recent removal of a near-term revenue driver from the profit and loss statement contribute to a challenging outlook for XOMA's stock.

XOMA (XOMA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About XOMA (XOMA) Forecast

Analysts have given XOMA (XOMA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, XOMA (XOMA) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $63.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $63.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

XOMA (XOMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.